As of 2024-10-13, the EV/EBITDA ratio of Novavax Inc (NVAX) is -7.04. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Novavax's latest enterprise value is 1,559.01 mil USD. Novavax's TTM EBITDA according to its financial statements is -221.43 mil USD. Dividing these 2 quantities gives us the above Novavax EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 15.1x - 17.6x | 16.4x |
| Forward P/E multiples | 17.0x - 32.5x | 24.4x |
| Fair Price | (20.72) - (21.61) | (25.46) |
| Upside | -265.4% - -272.4% | -303.2% |
| Date | EV/EBITDA |
| 2024-10-11 | -7.04 |
| 2024-10-10 | -7.31 |
| 2024-10-09 | -7.15 |
| 2024-10-08 | -7.41 |
| 2024-10-07 | -7.39 |
| 2024-10-04 | -7.82 |
| 2024-10-03 | -8.41 |
| 2024-10-02 | -8.60 |
| 2024-10-01 | -6.89 |
| 2024-09-30 | -7.11 |
| 2024-09-27 | -7.60 |
| 2024-09-26 | -6.76 |
| 2024-09-25 | -6.69 |
| 2024-09-24 | -7.59 |
| 2024-09-23 | -7.24 |
| 2024-09-20 | -7.32 |
| 2024-09-19 | -7.03 |
| 2024-09-18 | -7.06 |
| 2024-09-17 | -7.33 |
| 2024-09-16 | -7.53 |
| 2024-09-13 | -7.82 |
| 2024-09-12 | -6.60 |
| 2024-09-11 | -6.87 |
| 2024-09-10 | -7.16 |
| 2024-09-09 | -7.22 |
| 2024-09-06 | -6.39 |
| 2024-09-05 | -6.62 |
| 2024-09-04 | -6.56 |
| 2024-09-03 | -7.14 |
| 2024-08-30 | -6.93 |
| 2024-08-29 | -6.22 |
| 2024-08-28 | -6.03 |
| 2024-08-27 | -6.04 |
| 2024-08-26 | -6.30 |
| 2024-08-23 | -6.65 |
| 2024-08-22 | -6.63 |
| 2024-08-21 | -7.34 |
| 2024-08-20 | -7.39 |
| 2024-08-19 | -8.03 |
| 2024-08-16 | -7.35 |
| 2024-08-15 | -7.12 |
| 2024-08-14 | -6.79 |
| 2024-08-13 | -6.77 |
| 2024-08-12 | -6.55 |
| 2024-08-09 | -6.37 |
| 2024-08-08 | -6.43 |
| 2024-08-07 | -5.72 |
| 2024-08-06 | -6.32 |
| 2024-08-05 | -6.21 |
| 2024-08-02 | -6.50 |